Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use
暂无分享,去创建一个
[1] D. Strunk,et al. Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] J. Burns,et al. Versatile graphene biosensors for enhancing human cell therapy. , 2018, Biosensors & bioelectronics.
[3] C. Simmons,et al. Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering , 2018, Stem cells international.
[4] M. Ikeya,et al. Generation and Applications of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells , 2018, Stem cells international.
[5] Anthony Atala,et al. An Industry‐Driven Roadmap for Manufacturing in Regenerative Medicine , 2018, Stem cells translational medicine.
[6] Robert Wilson. Design of experiment in assessing robustness and for qualification of a cell-based potency assay. , 2018, Bioanalysis.
[7] Q. Guan,et al. Inducible indoleamine 2,3-dioxygenase 1 and programmed death ligand 1 expression as the potency marker for mesenchymal stromal cells. , 2018, Cytotherapy.
[8] F. Cerignoli,et al. In vitro immunotherapy potency assays using real-time cell analysis , 2018, PloS one.
[9] G. Gibson,et al. Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach. , 2018, Cell reports.
[10] M. Introna,et al. Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. , 2018, Cytotherapy.
[11] G. Lucchini,et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM) , 2018, Bone Marrow Transplantation.
[12] J. Vives,et al. Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells , 2018, Cytotechnology.
[13] C. Librach,et al. Angiogenic potency evaluation of cell therapy candidates by a novel application of the in vitro aortic ring assay , 2017, Stem Cell Research & Therapy.
[14] M. Hoefnagel,et al. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. , 2017, Cytotherapy.
[15] D. Sumstad,et al. Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture , 2017, Transfusion.
[16] G. Lajoie,et al. High Aldehyde Dehydrogenase Activity Identifies a Subset of Human Mesenchymal Stromal Cells with Vascular Regenerative Potential , 2017, Stem cells.
[17] H. Hackstein,et al. Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid , 2017, Stem Cell Research & Therapy.
[18] M. Pittenger,et al. Concise Review: MSC‐Derived Exosomes for Cell‐Free Therapy , 2017, Stem cells.
[19] A. Majumdar,et al. Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product , 2017, Stem Cell Research & Therapy.
[20] F. Catani,et al. Potency Biomarker Signature Genes from Multiparametric Osteogenesis Assays: Will cGMP Human Bone Marrow Mesenchymal Stromal Cells Make Bone? , 2016, PloS one.
[21] J. García-López,et al. Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells. , 2016, Cytotherapy.
[22] T. Ritter,et al. Development of a flow cytometry-based potency assay for measuring the in vitro immunomodulatory properties of mesenchymal stromal cells. , 2016, Immunology letters.
[23] A. Dietz,et al. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production , 2016, Stem Cell Research & Therapy.
[24] G. Lucchini,et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey , 2016, Haematologica.
[25] R. Schäfer,et al. Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy , 2016, Transfusion Medicine and Hemotherapy.
[26] A. Ho,et al. Indoleamine 2,3-dioxygenase mediates inhibition of virus-specific CD8(+) T cell proliferation by human mesenchymal stromal cells. , 2016, Cytotherapy.
[27] P. Hematti. Characterization of mesenchymal stromal cells: potency assay development , 2016, Transfusion.
[28] K. Bieback,et al. Characterization of mesenchymal stem or stromal cells: tissue sources, heterogeneity, and function , 2016, Transfusion.
[29] Peter W Zandstra,et al. Quality cell therapy manufacturing by design , 2016, Nature Biotechnology.
[30] A. Schambach,et al. Massive Clonal Selection and Transiently Contributing Clones During Expansion of Mesenchymal Stem Cell Cultures Revealed by Lentiviral RGB‐Barcode Technology , 2016, Stem cells translational medicine.
[31] T. Bliss,et al. High-Resolution Microfluidic Single-Cell Transcriptional Profiling Reveals Clinically Relevant Subtypes among Human Stem Cell Populations Commonly Utilized in Cell-Based Therapies , 2016, Front. Neurol..
[32] M. Toungouz,et al. The Immunomodulatory Potential of Mesenchymal Stromal Cells: A Story of a Regulatory Network , 2016, Journal of immunotherapy.
[33] S. Ferguson,et al. An in vitro expansion score for tissue‐engineering applications with human bone marrow‐derived mesenchymal stem cells , 2016, Journal of tissue engineering and regenerative medicine.
[34] Ivan Martin,et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. , 2016, Cytotherapy.
[35] L. Turchetto,et al. Quality Control Assays for Clinical-Grade Human Mesenchymal Stromal Cells: Methods for ATMP Release. , 2016, Methods in molecular biology.
[36] L. Turchetto,et al. Quality Control Assays for Clinical-Grade Human Mesenchymal Stromal Cells: Validation Strategy. , 2016, Methods in molecular biology.
[37] M. Pittenger,et al. Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects. , 2016, Transfusion medicine reviews.
[38] K. Keyvanfar,et al. Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency. , 2015, Cytotherapy.
[39] A. Reinisch,et al. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance , 2015, Stem Cell Research & Therapy.
[40] Vivek Tanavde,et al. Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material. , 2015, Cytotherapy.
[41] P. Kruzliak,et al. Validation of shortened 2-day sterility testing of mesenchymal stem cell-based therapeutic preparation on an automated culture system , 2015, Cell and Tissue Banking.
[42] Michael Raghunath,et al. Establishing Criteria for Human Mesenchymal Stem Cell Potency , 2015, Stem cells.
[43] M. Boutros,et al. Functional fingerprinting of human mesenchymal stem cells using high-throughput RNAi screening , 2015, Genome Medicine.
[44] M. Mcgrogan,et al. Cell injury-induced release of FGF2: relevance to intracerebral mesenchymal stromal cell transplantations. , 2015 .
[45] TorreMaria Luisa,et al. Ex Vivo Expanded Mesenchymal Stromal Cell Minimal Quality Requirements for Clinical Application , 2015 .
[46] K. Hoffmann,et al. Cryopreservation does not alter main characteristics of Good Manufacturing Process-grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation. , 2015, Cytotherapy.
[47] John M Centanni,et al. A reproducible immunopotency assay to measure mesenchymal stromal cell-mediated T-cell suppression. , 2015, Cytotherapy.
[48] B. Thompson,et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.
[49] J. Trouvin,et al. The challenges of potency assay development for cell-based medicinal products in Europe , 2015 .
[50] D. Prockop,et al. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo , 2014, Proceedings of the National Academy of Sciences.
[51] Asha A. Nair,et al. High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells , 2014, Journal of cellular biochemistry.
[52] B. Nilsson,et al. Cryopreserved Mesenchymal Stromal Cells Display Impaired Immunomodulatory and Therapeutic Properties ? , 2022 .
[53] Yaojiong Wu,et al. Epigenetic changes of mesenchymal stem cells in three-dimensional (3D) spheroids , 2014, Journal of cellular and molecular medicine.
[54] ViswanathanSowmya,et al. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. , 2014 .
[55] J. Daniels,et al. Challenges in the development of a reference standard and potency assay for the clinical production of RAFT tissue equivalents for the cornea. , 2014, Regenerative medicine.
[56] R. Puri,et al. MSC-based product characterization for clinical trials: an FDA perspective. , 2014, Cell stem cell.
[57] J. James,et al. Can we fix it? Evaluating the potential of placental stem cells for the treatment of pregnancy disorders. , 2014, Placenta.
[58] A. Hmadcha,et al. Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. , 2014, Stem cells and development.
[59] E. Alici,et al. Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data , 2014, Stem Cell Research & Therapy.
[60] K. Tarte,et al. Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. , 2013, Cytotherapy.
[61] K. Tarte,et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies--bridging scientific observations and regulatory viewpoints. , 2013, Cytotherapy.
[62] Joelle Dulong,et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. , 2013, Stem cells and development.
[63] H. Northoff,et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells , 2013, BMC Medicine.
[64] Mélanie Gadelorge,et al. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review , 2013, Stem Cell Research & Therapy.
[65] M. Neubauer,et al. Mesenchymal stromal cell characteristics vary depending on their origin. , 2013, Stem cells and development.
[66] L. Moroni,et al. Human mesenchymal stem cells: A bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues , 2013, Journal of cellular physiology.
[67] P. de Coppi,et al. Therapeutic potential of amniotic fluid stem cells. , 2013, Current stem cell research & therapy.
[68] D. Covas,et al. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH. , 2013, Experimental hematology.
[69] Jacques Galipeau,et al. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? , 2013, Cytotherapy.
[70] Christopher A Bravery,et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. , 2013, Cytotherapy.
[71] D. Phinney. Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy , 2012, Journal of cellular biochemistry.
[72] M. Toungouz,et al. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. , 2012, Immunology letters.
[73] Rochelle Cutrone,et al. Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. , 2012, Cytotherapy.
[74] Byung-Soo Kim,et al. Transplantation of cord blood mesenchymal stem cells as spheroids enhances vascularization. , 2012, Tissue engineering. Part A.
[75] T. Redmer,et al. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. , 2012, Cytotherapy.
[76] T. Young,et al. The influence of spheroid formation of human adipose-derived stem cells on chitosan films on stemness and differentiation capabilities. , 2012, Biomaterials.
[77] R. Romieu-Mourez,et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.
[78] Katie C. Russell,et al. Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency , 2011, Biotechnology and bioengineering.
[79] Arnold I Caplan,et al. The MSC: an injury drugstore. , 2011, Cell stem cell.
[80] M. Najar,et al. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from Wharton's jelly without enzymatic treatment. , 2011, Stem cells and development.
[81] M. Yarmush,et al. A mesenchymal stem cell potency assay. , 2011, Methods in molecular biology.
[82] Soichiro Saito,et al. Use of BAC array CGH for evaluation of chromosomal stability of clinically used human mesenchymal stem cells and of cancer cell lines , 2011, Human Cell.
[83] Nikolay Bazhanov,et al. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties , 2010, Proceedings of the National Academy of Sciences.
[84] Katie C. Russell,et al. In Vitro High‐Capacity Assay to Quantify the Clonal Heterogeneity in Trilineage Potential of Mesenchymal Stem Cells Reveals a Complex Hierarchy of Lineage Commitment , 2010, Stem cells.
[85] T. Moccetti,et al. A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice , 2009, Journal of Translational Medicine.
[86] L. Isola,et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[87] A. Reinisch,et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. , 2008, Tissue engineering. Part C, Methods.
[88] Peter R. Brink,et al. Culturing of Human Mesenchymal Stem Cells as Three-dimensional Aggregates Induces Functional Expression of CXCR4 That Regulates Adhesion to Endothelial Cells* , 2008, Journal of Biological Chemistry.
[89] R. Consolini,et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood , 2006 .
[90] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[91] O. Lee,et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. , 2004, Blood.
[92] H. Lorenz,et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. , 2001, Tissue engineering.
[93] Arnold I. Caplan,et al. Mesenchymal Stem Cells , 1991, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[94] H. Broxmeyer,et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. , 1980, Blood.
[95] A. Friedenstein,et al. STROMAL CELLS RESPONSIBLE FOR TRANSFERRING THE MICROENVIRONMENT OF THE HEMOPOIETIC TISSUES: Cloning In Vitro and Retransplantation In Vivo , 1974, Transplantation.
[96] A. Friedenstein,et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.
[97] Reflection paper on stem cell-based medicinal products , 2022 .